Nasdaq stocks posting largest percentage increases
AP - Tue Oct 21, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
IMDZ: 26.11 (+2.75), ENPH: 13.80 (+1.57), EGLT: 5.73 (+0.86), ISRL: 131.99 (-11.99), QVCB: 25.35 (+0.21), QVCA: 25.41 (+0.70), SHLD: 34.79 (-0.17)
2 Oversold Stocks Under $10 Ready to Bounce Higher
at The Street - Fri Oct 17, 8:05AM CDT
Oversold can always get more oversold, but it's also an area from which a stock can experience a powerful bounce higher.
AMKR: 7.40 (+0.40), EGLT: 5.73 (+0.86)
Egalet (EGLT) Shows Strength: Stock Moves 7.1% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 8:46AM CDT
Egalet (EGLT) was a big mover last session, with shares rising over 7% on the day.
LCI: 44.96 (+1.04), EGLT: 5.73 (+0.86), SHPG: 185.80 (+1.21), CEMP: 12.19 (-0.03)
Egalet Announces Update on Clinical Development Plan for Abuse-Deterrent Morphine Egalet-001
GlobeNewswire - Tue Sep 23, 3:00PM CDT
Egalet Corporation (Nasdaq:EGLT) (Egalet) today announced an update to the clinical development plan for Egalet-001, an abuse-deterrent, extended-release, oral morphine product in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. Based on the clinical data generated thus far, the Company will need to conduct additional clinical trials to strengthen the new drug application (NDA) for Egalet-001. Egalet plans to schedule a meeting in the fourth quarter of 2014 with the U.S. Food and Drug Administration (FDA) to discuss the totality of the clinical data from the studies completed and the appropriate registration path forward for Egalet-001.
EGLT: 5.73 (+0.86)
Egalet Announces Issuance of U.S. Patents Covering Guardian(TM) Technology and Product Candidates
GlobeNewswire - Thu Sep 11, 7:13AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet"
EGLT: 5.73 (+0.86)
Egalet to Present Data from Abuse-Deterrence Studies at PAINWeek 2014 in Las Vegas
GlobeNewswire - Thu Sep 04, 7:35AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet"
EGLT: 5.73 (+0.86)
Falling Earnings Estimates Signal Weakness Ahead for Egalet (EGLT) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 7:46AM CDT
Egalet has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
ENDP: 63.73 (+2.29), EGLT: 5.73 (+0.86), UTHR: 127.61 (+1.15), HPTX: 22.75 (+0.08)
Egalet Announces Successful End-of-Phase 2 Meeting With the FDA for Egalet-002
GlobeNewswire - Mon Aug 18, 7:40AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet"
EGLT: 5.73 (+0.86)
Egalet Reports Second Quarter 2014 Financial Results and Provides Business Update
PR Newswire - Tue Aug 12, 5:00AM CDT
Egalet Corporation (Nasdaq: EGLT) ("Egalet"
EGLT: 5.73 (+0.86)
Egalet Announces Topline Results From Bioequivalence Studies of Abuse-Deterrent Morphine, Egalet-001
GlobeNewswire - Wed Aug 06, 5:01AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet"
EGLT: 5.73 (+0.86)
Egalet to Present at the Canaccord Genuity Growth Conference on August 13
GlobeNewswire - Wed Jul 30, 7:40AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet"
EGLT: 5.73 (+0.86)
Egalet to Host Conference Call and Webcast to Discuss Second Quarter Financial Results on August 12, 2014
PR Newswire - Tue Jul 29, 8:30AM CDT
Egalet Corporation (Nasdaq: EGLT) ("Egalet"
EGLT: 5.73 (+0.86)